POM (UK), ?-only (U.S.)Routes OralIrbesartan (INN) (pronounced /?rb??s?rt?n/) is an impact of avapro on digestion II receptor antagonist used mainly for the treatment of hypertension. Irbesartan may also delay progression of impact of avapro on digestion nephropathy and is also indicated for the treatment of hypertension. Irbesartan was.

11–15 hoursExcretion Renal 20%, faecal 65%Therapeutic considerationsLicence data EU, USPregnancy cat. D (Au)Legal status impact of avapro on digestion (Au), POM impact of avapro on digestion ?-only (U.S.)Routes OralIrbesartan (INN) (pronounced /?rb??s?rt?n/) is an angiotensin II receptor antagonists, irbesartan is indicated for the treatment of hypertension. Irbesartan was developed by Sanofi Research (now part of sanofi-aventis). It is jointly marketed by sanofi-aventis and Bristol-Myers Squibb under the trade names Aprovel, Karvea, and Avapro.Contents [hide]1 Clinical use1.1 Indications1.2 Combination with impact of avapro on digestion References3 See also[edit] Clinical useMain article: Angiotensin II receptor antagonists, irbesartan is indicated for the impact of avapro on digestion of hypertension. Irbesartan was developed by Sanofi Research impact of avapro on digestion part of sanofi-aventis). It is jointly marketed impact of avapro on digestion sanofi-aventis and Bristol-Myers Squibb under the trade names to irbesartan preparations, impact of avapro on digestion CoAprovel, Karvezide, Avalide and Avapro HCT.[edit] References^ Lewis EJ, Hunsicker LG, Clarke.

EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, impact of avapro on digestion RC, Rohde R, Raz I; Collaborative Study.